Title:
ACRIDIN-9-YL-AMINE, QUINOLIN-9-YL-AMINE, 1 -AMINO-9H-THIOXANTHENE-9-ONE AND BENZO[B][1,5]NAPHTHYRI DIN-10-YL-AMINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR TREATING CANCER
Document Type and Number:
WIPO Patent Application WO/2021/142065
Kind Code:
A1
Abstract:
This disclosure provides a cridin-9-yl-amine, quinolin-9-yl-amine, 1- amino-9H-thioxanthene-9-one and benzo[b][l,5]naphthyridin-10- yl-amine derivatives and structurally related compounds for use as autophagy inhibitors for treating cancer. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 77 to 155; examples 1 to 22; compound A; compounds 1 to 21; tables 1 to 3).
Inventors:
HOU FRANK SHUJIE (US)
XUE JIAN (CN)
ZHAO YUSHAN (US)
MIAO DEZU (CN)
XUE JIAN (CN)
ZHAO YUSHAN (US)
MIAO DEZU (CN)
Application Number:
PCT/US2021/012424
Publication Date:
July 15, 2021
Filing Date:
January 07, 2021
Export Citation:
Assignee:
REYOUNG CORP (US)
REYOUNG DRUG DISCOVERY CO LTD (CN)
REYOUNG DRUG DISCOVERY CO LTD (CN)
International Classes:
C07D401/14; A61K31/382; A61K31/4192; A61K31/444; A61K31/4709; A61K31/473; A61K31/4745; A61K31/496; A61P35/00; C07D219/12; C07D221/08; C07D401/12; C07D409/12; C07D409/14; C07D471/04
Domestic Patent References:
| WO2016168721A1 | 2016-10-20 | |||
| WO2016011022A1 | 2016-01-21 | |||
| WO2012149186A2 | 2012-11-01 | |||
| WO2016150799A1 | 2016-09-29 | |||
| WO2006092395A1 | 2006-09-08 | |||
| WO2020243037A1 | 2020-12-03 | |||
| WO2016011022A1 | 2016-01-21 | |||
| WO2012149186A2 | 2012-11-01 | |||
| WO2012154879A2 | 2012-11-15 | |||
| WO2016168721A1 | 2016-10-20 |
Foreign References:
| US5886185A | 1999-03-23 |
Other References:
SONDHI SHAM M. ET AL: "Synthesis of Bis-acridine Derivatives Exhibiting Anticancer and Anti-inflammatory Activity", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 50, no. 2, 7 March 2013 (2013-03-07), US, pages 252 - 260, XP055787941, ISSN: 0022-152X, DOI: 10.1002/jhet.985
HE Z ET AL: "DNA threading bis(9-aminoacridine-4-carboxamides): Effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest", BIOORGANIC & MEDICINAL CHEMISTRY,, vol. 16, no. 8, 15 April 2008 (2008-04-15), pages 4390 - 4400, XP022617889, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2008.02.063
DOLLINGER SILKE ET AL: "A Chimeric Ligand Approach Leading to Potent Antiprion Active Acridine Derivatives: Design, Synthesis, and Biological Investigations", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 22, 29 September 2006 (2006-09-29), pages 6591 - 6595, XP055787925, ISSN: 0022-2623, DOI: 10.1021/jm060773j
JIANG, P.MIZUSHIMA, N., CELL RESEARCH, vol. 24, 2014, pages 69 - 79
KHAMBU, B. ET AL., LIVER RESEARCH, vol. 2, no. 3, 2018, pages 112 - 119
YANG, J.-S ET AL., BIOMEDICINE, vol. 7, no. 2, 2017, pages 8
SCHIATTARELLA, G. G.HILL, J. A., J. MOL. CELL CARDIOL., vol. 95, 2016, pages 86 - 93
KIMMELMAN, A. C.WHITE, E., CELL METABOLISM, vol. 25, no. 5, 2017, pages 1037 - 1043
LEVY, J. M. ET AL., NAT. REV. CANCER, vol. 17, no. 9, 2017, pages 528 - 542
JIANG, G.-M. ET AL., MOLECULAR CANCER, vol. 18, 2019, pages 7
GLICK, D. ET AL., THE JOURNAL OF PATHOLOGY, vol. 22, no. 1, 2010, pages 3 - 12
EGAN, D. F. ET AL., MOLECULAR CELL, vol. 59, no. 2, 2015, pages 285 - 297
RONAN, B. ET AL., NATURE CHEMICAL BIOLOGY, vol. 10, no. 120, 2014, pages 1013 - 1019
CAREW, J. S. ET AL., CLINICAL CANCER RESEARCH, vol. 23, no. 11, 2017, pages 2869 - 2879
MCAFEE, Q. ET AL., PROC NATL ACADSCI USA (PNAS), vol. 109, no. 21, 2012, pages 8253 - 8258
GOODALL, M. L. ET AL., AUTOPHAGY, vol. 10, no. 6, 2014, pages 1120 - 1136
OIEN, D. B. ET AL.: "Repurposing quinacrine for treatment-refractory cancer", SEMINARS IN CANCER BIOLOGY, 2019
WANG, T. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, 2015, pages 3025 - 3035
REBECCA, V. W. ET AL., CANCER DISCOVERY, vol. 7, no. 11, 2017, pages 1266 - 1283
HE Z ET AL: "DNA threading bis(9-aminoacridine-4-carboxamides): Effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest", BIOORGANIC & MEDICINAL CHEMISTRY,, vol. 16, no. 8, 15 April 2008 (2008-04-15), pages 4390 - 4400, XP022617889, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2008.02.063
DOLLINGER SILKE ET AL: "A Chimeric Ligand Approach Leading to Potent Antiprion Active Acridine Derivatives: Design, Synthesis, and Biological Investigations", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 22, 29 September 2006 (2006-09-29), pages 6591 - 6595, XP055787925, ISSN: 0022-2623, DOI: 10.1021/jm060773j
JIANG, P.MIZUSHIMA, N., CELL RESEARCH, vol. 24, 2014, pages 69 - 79
KHAMBU, B. ET AL., LIVER RESEARCH, vol. 2, no. 3, 2018, pages 112 - 119
YANG, J.-S ET AL., BIOMEDICINE, vol. 7, no. 2, 2017, pages 8
SCHIATTARELLA, G. G.HILL, J. A., J. MOL. CELL CARDIOL., vol. 95, 2016, pages 86 - 93
KIMMELMAN, A. C.WHITE, E., CELL METABOLISM, vol. 25, no. 5, 2017, pages 1037 - 1043
LEVY, J. M. ET AL., NAT. REV. CANCER, vol. 17, no. 9, 2017, pages 528 - 542
JIANG, G.-M. ET AL., MOLECULAR CANCER, vol. 18, 2019, pages 7
GLICK, D. ET AL., THE JOURNAL OF PATHOLOGY, vol. 22, no. 1, 2010, pages 3 - 12
EGAN, D. F. ET AL., MOLECULAR CELL, vol. 59, no. 2, 2015, pages 285 - 297
RONAN, B. ET AL., NATURE CHEMICAL BIOLOGY, vol. 10, no. 120, 2014, pages 1013 - 1019
CAREW, J. S. ET AL., CLINICAL CANCER RESEARCH, vol. 23, no. 11, 2017, pages 2869 - 2879
MCAFEE, Q. ET AL., PROC NATL ACADSCI USA (PNAS), vol. 109, no. 21, 2012, pages 8253 - 8258
GOODALL, M. L. ET AL., AUTOPHAGY, vol. 10, no. 6, 2014, pages 1120 - 1136
OIEN, D. B. ET AL.: "Repurposing quinacrine for treatment-refractory cancer", SEMINARS IN CANCER BIOLOGY, 2019
WANG, T. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, 2015, pages 3025 - 3035
REBECCA, V. W. ET AL., CANCER DISCOVERY, vol. 7, no. 11, 2017, pages 1266 - 1283
Attorney, Agent or Firm:
BERKOWITZ, Benjamin et al. (US)
Download PDF: